Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

OncoTargets and Therapy
Thomas A OllilaAdam J Olszewski

Abstract

Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy options. These options often lack comparative evidence or are characterized by low response rates and short remission duration in relapsed/refractory disease. The approval of mogamulizumab, a humanized, glycoengineered IgG1κ monoclonal antibody targeting the chemokine receptor type 4 (CCR4) chemokine receptor, brings a novel tool into the spectrum of treatment options for advanced CTCL and adult T-cell leukemia/lymphoma (ATLL). CCR4 is expressed in almost all cases of ATLL, and in a majority of CTCLs, particularly when blood involvement is present. In a Phase III randomized trial, mogamulizumab was associated with 28% overall response rate among patients with relapsed CTCL, median progression-free survival of 7.7 months, and median duration of remission of 14.1 months. Responses are more frequent among patients with Sézary syndrome and within the blood compartment. Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogamulizumab may result in severe or refractory graft vs host disease after allogeneic bone marrow transp...Continue Reading

Citations

Jul 20, 2019·Clinical Journal of Oncology Nursing·Marianne TawaWendy Cantrell
Jan 7, 2020·Expert Opinion on Drug Metabolism & Toxicology·Miao MiaoGuangdi Li
Oct 28, 2019·The Annals of Pharmacotherapy·Donald C MooreSteven I Park
Feb 9, 2020·Current Hematologic Malignancy Reports·Till BraunMarco Herling
Feb 29, 2020·Molecular Oncology·Haoyu WangZhirui Wang
Sep 12, 2020·Dermatologic Therapy·Shekhar Neema, Anupam Das
Oct 28, 2019·Frontiers in Oncology·Martina FerrantiMauro Alaibac
Oct 17, 2019·Journal of Clinical Medicine·Emilio Sanseviero
Oct 24, 2020·British Journal of Haematology·Julia J ScarisbrickPablo L Ortiz-Romero
Nov 30, 2020·Cellular Signalling·Dylan Scott EigerSudarshan Rajagopal
Dec 18, 2020·Frontiers in Endocrinology·Milad RouhimoghadamEdward J Filardo
Apr 24, 2021·Expert Review of Clinical Immunology·Antreas PavlidisEvangelia Papadavid
Apr 4, 2021·European Journal of Immunology·Jan P NicolayEmilio Berti
Dec 15, 2020·Pharmacology & Therapeutics·Gregory P TakacsJeffrey K Harrison
May 12, 2021·Cytokine·Paulo Henrique Rosa da SilvaMarcelo José Barbosa Silva
May 20, 2021·Seminars in Immunopathology·Julien Catherine, Florence Roufosse
Jun 2, 2021·Biochemical Society Transactions·Wing Yee Lai, Anja Mueller
Jul 29, 2021·JACC. Case Reports·Jennifer M KwanLauren A Baldassarre
Jul 18, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·R A CowanM C Medley
Dec 5, 2021·European Journal of Haematology·Kisato NosakaTakeshi Takahashi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
flow cytometry

Clinical Trials Mentioned

NCT00355472
NCT00920790
NCT01626664
NCT01192984
NCT00888927
NCT01728805
NCT03309878
NCT02476123

Software Mentioned

MAVORIC
SWAT
mSWAT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.